ATAI
AtaiBeckleyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The post-earnings company update kept the core bull thesis intact: BPL-003 Phase 3 is still slated for Q2 2026, VLS-01 topline is still expected in Q4 2026, and management says the balance sheet funds the company into 2029 [#8-K-2026-05-12] [#10-Q-2026-05-12]. A secondary post-print signal also appears constructive, with StockAnalysis surfacing a Canaccord target increase to $15 from $14 after the release.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +13.2.
What can break
Clinical-stage concentration risk is high: BPL-003 is the lead value driver, while VLS-01 and EMP-01 remain developmental and subject to trial-readout volatility.
Momentum
67
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $8.00 · Bear $2.50
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.45
Why
Momentum67 · Δ7d +13.2
Value41 · Δ7d +0.0
Sentiment62 · Δ7d -12.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
67
34% active weight
Current posture
7d trendImproving
Δ7d
+13.2
Δ21d
+8.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
62
33% active weight
Current posture
7d trendSoftening
Δ7d
-12.9
Δ21d
-18.4
Why this grade
Composite grade B. Momentum 67.1 / Value 41.1 / Sentiment 62.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.77B
Beta
1.62
Shares Out
363.19M
P/E (TTM) · Derived
-5.3
P/S (TTM)
464.95
P/FCF (TTM) · Derived
-10.16
Rev YoY
+1772.5%
EPS YoY
-71.5%
Gross Margin
-
Op Margin
-3272.5%
Net Debt
-$38.83M
Current Ratio
7.90
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology